Top coverage from the European Respiratory Society (ERS) Congress 2024 spanned various topics, including artificial intelligence–powered robots transforming respiratory care and late-breaking findings on an epilepsy drug showing promise for treating obstructive sleep apnea.
A SUMMIT trial analysis showed how tirzepatide improves cardiovascular and kidney health in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).
Presentations at the European Hematology Association (EHA) 2024 Congress were encouraging for their data on innovations within the hematology/oncology space that are reshaping treatment outcomes.
The 66th American Society of Hematology (ASH) Annual Meeting & Exposition will take place December 7-10, 2024, in San Diego, California.
In part 2 of our interview, Cesar Davila-Chapa, MD, discusses key findings, limitations, and future research directions from his study on racial disparities in idiopathic pulmonary fibrosis (IPF) outcomes.
Presentations at the 2024 Asembia Specialty Pharmacy Summit focused on reshaping specialty pharmacy while keeping patients front and center.
Palliative care is quality care, and providers and health systems need to do a better job at ensuring there is equity in palliative care, said Nadine J. Barrett, PhD, MA, MS, FACCC, of Wake Forest University and the Association of Cancer Care Centers.
Attendees of the centennial American Heart Association (AHA) conference commend the meeting's ability to bring together diverse, interdisciplinary perspectives from across the globe.
The poster session, “Behind the Curtain: How Healthcare Policy Shapes Patient Outcomes,” took place on the final day of the American Heart Association Scientific Session.
Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
The implementation of a risk evaluation mitigation strategy (REMS) program to monitor patients on mavacamten further supports its real-world use, according to Milind Desai, MD, Cleveland Clinic.
Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.
Results bring more competition to treat this genetically driven target for cardiovascular risk.
New discoveries in atherosclerosis pathways have shed light on the active mechanisms in other diseases such as chronic kidney disease (CKD) and HIV, paving the way for furture therapeutics.
The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.
The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse events in patients less at risk of cardiomyopathy.
Follow-up results for the FINEARTS-HF trial focused on specific results for women and men, hyperkalemia risk, and an analysis of the elements of its composite end point.
Lead study author Alexander T. Sandhu, MD, MS, of Stanford said the team will evaluate behavior to understand the results.
A decision from the American Board of Medical Specialties will be made about a new cardiovascular board by this upcoming February.
The connection between brain, mental, and cardiovascular health needs considerable more attention, argues Maureen Hood, PhD, RN, Uniformed Services University.
Posters presented at the American Heart Association Scientific Sessions included results that show how persistent disparities are in cardiovascular (CV) health.
Payers and employers have tightened access to the glucagon-like peptide 1 receptor agonist class once these therapies became more commonly prescribed for obesity.
The upcoming Greater Philadelphia Business Coalition on Health (GPBCH) 2024 Mental Health Summit aims to address the growing recognition among employers of the critical role mental health plays in workplace productivity and overall well-being.
Rebekah Walker, PhD, a first-time participant from the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, shares the offerings and opportunities at the 2024 American Heart Association (AHA) meeting that excited her and her team.
Therapies for obesity and inhibitors for lipoprotein(a) (Lp[a]) are among those to be featured at the American Heart Association (AHA) Scientific Sessions November 16-18, 2024, which will take place in Chicago, where the AHA was founded 100 years ago.
Mabel Mardones, MD, Rocky Mountain Cancer Centers, discusses the future of HR+/HER2– breast cancer treatment, focusing on the importance of biomarkers and the potential of SERDs to improve patient outcomes.
As part of our coverage of the biennial AIDS conference from the International AIDS Society, we spoke with Madalitso Juwayeyi, program manager at FACT-Malawi, to learn more about her organization and how it strives to serve the sexual and reproductive health needs of adolescent girls and young women in her native Malawi.
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, particularly regarding immune-related adverse events.
Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, discusses insights from the FLAME trial analysis and the ICS-RECODE meta-analysis.
New legislation would clarify rules around value-based contracts in Medicaid, and a new model is expanding access to gene therapies, explained Adam Colborn, JD, of AMCP.
